Eli Lilly Wins FDA Approval for Weekly Insulin as J&J and Bristol Myers Plan Job Cuts

Key Facts

1Eli Lilly received FDA approval for a once-weekly basal insulin injection.

2Johnson & Johnson and Bristol Myers Squibb announced plans for job cuts.

Eli Lilly received FDA approval for a once-weekly basal insulin injection, marking a product milestone for the company's diabetes portfolio. Medical Marketing and Media reported the regulatory win alongside announcements from Johnson & Johnson and Bristol Myers Squibb regarding plans to reduce their workforce as part of strategic realignments.

LLY closed at $1181.89 on September 24, 2026, having reached a day high of $1197.79. Meanwhile, JNJ closed at $270.68 on September 24, 2026, as the company's job cuts reflect broader cost-management efforts currently impacting the pharmaceutical sector.